Free tool
FAERS Monitor: Pulmozyme
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 103532 or its brand name (Pulmozyme, Dornase Alfa). Reports on generic versions are filed under their own applications.
Reports
19,634
Serious
13,482
69% of reports
Hospitalization
10,667
Death reported
827
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- infective pulmonary exacerbation of cystic fibrosis2,316
- cystic fibrosis1,776
- hospitalisation1,320
- pneumonia1,308
- cough1,000
- off label use975
- infection950
- no adverse event944
- dyspnoea926
- condition aggravated623
- headache548
- pulmonary function test decreased494
- death491
- fatigue475
- malaise473
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 15 |
| 2005 | 15 |
| 2006 | 18 |
| 2007 | 25 |
| 2008 | 44 |
| 2009 | 28 |
| 2010 | 85 |
| 2011 | 277 |
| 2012 | 217 |
| 2013 | 240 |
| 2014 | 438 |
| 2015 | 793 |
| 2016 | 1,160 |
| 2017 | 1,288 |
| 2018 | 2,093 |
| 2019 | 3,972 |
| 2020 | 3,601 |
| 2021 | 1,263 |
| 2022 | 1,076 |
| 2023 | 848 |
| 2024 | 1,040 |
| 2025 | 662 |
| 2026 | 435 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,034,525 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| infective pulmonary exacerbation of cystic fibrosisSignal | 2,316 | 792.2 | 752.2 | 1,051,941 |
| cystic fibrosisSignal | 1,776 | 505.2 | 478.4 | 607,144 |
| pulmonary function test decreasedSignal | 494 | 136.1 | 124.1 | 58,682 |
| hospitalisationSignal | 1,320 | 9.3 | 8.8 | 9,723 |
| infectionSignal | 950 | 7.1 | 6.6 | 4,948 |
| no adverse eventSignal | 944 | 5.6 | 5.3 | 3,580 |
| pneumoniaSignal | 1,308 | 4.3 | 4.1 | 3,399 |
| coughSignal | 1,000 | 3.8 | 3.6 | 2,109 |
| condition aggravatedSignal | 623 | 2.2 | 2.0 | 410 |
| dyspnoea | 926 | 1.8 | 1.6 | 307 |
| off label use | 975 | 1.2 | 1.1 | 32 |
| malaise | 473 | 1.2 | 1.1 | 10 |
| headache | 548 | 0.9 | 0.9 | 2 |
| fatigue | 475 | 0.7 | 0.6 | 90 |
| death | 491 | 0.6 | 0.6 | 127 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.